Could the J&J - Vanderbilt partnership to develop schizophrenia therapeutics (reference below) result in a successful, synergistic business model between academia and biopharma? It may seem to be a natural evolution for Universities to move up the value chain by leveraging their infrastructure and delving into drug optimization, preclinical and possibly even clinical studies to drive higher value for their assets. However this opportunity may only apply to a few academic institutions with the appropriate culture and vision to recognize and embrace this potential opportunity...
http://www.fiercebiotech.com/story/j-j-vanderbilt-ink-rich-partnering-deal/2009-01-09?utm_medium=rss&utm_source=rss&cmp-id=OTC-RSS-FB0
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment